Recent News
Below are our most recent news releases. Click on a news item to read more.
Apr 26, 2022 – MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)
Mar 16, 2022 – MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies
Mar 15, 2022 – MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Nov 09, 2021 – MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
Oct 14, 2021 – MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies
Sep 28, 2021 – MAIA Biotechnology, Inc. Announces the Appointment of Steven M. Chaouki to Its Board of Directors
Sep 15, 2021 – MAIA Biotechnology, Inc. Announces Formation of Scientific Advisory Board
Aug 17, 2021 – MAIA Biotechnology, Inc. Appoints Joseph F. McGuire as Chief Financial Officer and Provides Corporate Update
Aug 04, 2021 – MAIA Biotechnology, Inc. Announces Additions to Executive Team and Board of Directors
May 19, 2021 – MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies
Mar 25, 2021 – MAIA Biotechnology to Present at Upcoming Investor Conferences
Events
Upcoming Events
Currently, there are no future events scheduled for MAIA. Please check back soon.
Past Events
Nov 10-14, 2021 – Society for Immunotherapy of Cancer (SITC) 2021 Conference
Mar 29-Apr 2, 2021 – MedInvest Spring 2021 Oncology Investor Conference
Mar 23-25, 2021 – Keiretsu Midwest Angel Forum